These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27190083)

  • 1. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
    Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
    Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
    Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
    J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
    Toyoda F; Tanaka Y; Ota A; Shimmura M; Kinoshita N; Takano H; Matsumoto T; Tsuji J; Kakehashi A
    J Diabetes Res; 2014; 2014():672590. PubMed ID: 25215304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules.
    Okayama N; Omi H; Okouchi M; Imaeda K; Kato T; Akao M; Imai S; Shimizu M; Fukutomi T; Itoh M
    J Diabetes Complications; 2002; 16(5):321-6. PubMed ID: 12200074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K; Sato N; Sato K; Shimizu H; Mori M
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of nitric oxide production by aldose reductase inhibitor in human endothelial cells cultured in high-glucose medium.
    Okuda Y; Kawashima K; Suzuki S; Asakura Y; Asano M; Tsurumaru K; Dai H; Tachi Y; Bannai C; Saitoh M; Yamashita K
    Life Sci; 1997; 60(3):PL53-6. PubMed ID: 9000650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protective effect of epalrestat against high glucose-induced endothelial cell injuries].
    Wang F; Hong Q; Liu G
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Jun; 32(7):940-3. PubMed ID: 22820572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
    Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V
    J Pharmacol Sci; 2008 Jul; 107(3):231-7. PubMed ID: 18635918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations.
    Huang Z; Hong Q; Zhang X; Xiao W; Wang L; Cui S; Feng Z; Lv Y; Cai G; Chen X; Wu D
    Cell Commun Signal; 2017 Jan; 15(1):3. PubMed ID: 28057038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
    Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
    Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
    Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
    Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranirestat as a therapeutic aldose reductase inhibitor for diabetic complications.
    Giannoukakis N
    Expert Opin Investig Drugs; 2008 Apr; 17(4):575-81. PubMed ID: 18363521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
    Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
    Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.